Foci Pharmaceutical Co., Ltd. and HongRi Pharmaceutical Co., Ltd. jointly expand the market of Northwest traditional Chinese medicine formula granules

[China Pharmaceutical network enterprise news] foci pharmaceutical announced on July 12 that recently, the company and Tianjin HongRi Pharmaceutical Co., Ltd (hereinafter referred to as "HongRi pharmaceutical") signed a joint venture agreement, and the two sides will carry out cooperation in the production and sales of traditional Chinese medicine formula particles Foci pharmaceutical introduced that the company held the 18th meeting of the 6th board of directors on July 10, 2018, and considered and passed the proposal on signing the joint venture cooperation agreement with Tianjin HongRi Pharmaceutical Co., Ltd According to the signed agreement, both parties agree to rely on the production process system, quality standards and channel services of Beijing kangrentang Pharmaceutical Co., Ltd (hereinafter referred to as "Beijing kangrentang"), a wholly-owned subsidiary of HongRi pharmaceutical industry, to jointly increase the capital of Beijing kangrentang, a wholly-owned subsidiary of HongRi pharmaceutical industry, and Gansu foci Pharmaceutical Industry Development Co., Ltd., a wholly-owned subsidiary of foci pharmaceutical industry Exhibition Co., Ltd (hereinafter referred to as "drug source industry development company") develops a brand-new production enterprise of traditional Chinese medicine formula granules At the same time, both parties jointly invested to establish Gansu focihongri drug source industry sales Co., Ltd (tentative name, hereinafter referred to as "drug source industry sales company") Integrate the marketing resources of formula granules in the Northwest market of HongRi pharmaceutical, carry out the sales of formula granules approved by Gansu Province and the sales of formula granules commissioned by the wholly-owned subsidiary of HongRi pharmaceutical in the demand capacity of the northwest region, and expand the market of formula granules in the northwest region Beijing kangrentang, a wholly-owned subsidiary of HongRi pharmaceutical, and foci Pharmaceutical Co., Ltd jointly invested in the pharmaceutical industry development company, foci Pharmaceutical Co., Ltd said Among them, Beijing kangrentang, a wholly-owned subsidiary of HongRi pharmaceutical, increased its capital to pharmaceutical industry development company in the form of currency; Foci pharmaceutical takes the assessed net assets of pharmaceutical industry development company, a wholly-owned subsidiary including the existing registered capital, as its capital contribution, with a capital contribution of 73 million yuan, and the equivalent net assets exceeding 73 million yuan shall be replaced by the investment of Beijing kangrentang, a wholly-owned subsidiary of Party A, and paid to Party B After the capital increase, the shareholding structure is 52% owned by Party A, 40% owned by foci pharmaceutical and 8% owned by the management team Pharmaceutical industry sales company: both parties contribute in currency, with HongRi pharmaceutical holding 40%, foci pharmaceutical holding 52%, and management team holding 8% Carry out the sales of formula granules approved by Gansu Province and the sales of formula granules commissioned by HongRi pharmaceutical's wholly-owned subsidiary in Northwest China It is understood that HongRi Pharmaceutical Co., Ltd is one of the leading enterprises of traditional Chinese medicine formula granules in China A complete set of technology and quality standard of traditional Chinese medicine formula granules has been established based on the research of infrared spectrum technology, chromatographic characteristic fingerprint and online quality control technology, which meets the needs of industrial production and clinical practice In this cooperation with HongRi pharmaceutical industry, the two sides will actively seize the opportunity of TCM formula granules policy, give full play to their respective advantages and synergies, jointly invest in the establishment of TCM formula granules production enterprises and marketing enterprises, and jointly expand the market of TCM formula granules in Northwest China by increasing investment in the construction of production base, strengthening the construction of marketing channels Fosci pharmaceutical also said that the cooperation between the company and HongRi pharmaceutical industry is in line with the company's future development plan and extends to the upstream and downstream industrial chain layout, which is conducive to building a new profit growth point and further improving the company's business performance It is understood that the standard of traditional Chinese medicine granules in Gansu Province (Trial) (volume) was released in September last year This volume of "standard" contains the standard of 193 kinds of traditional Chinese medicine formula granules commonly used in Gansu Province It can basically cover the commonly used traditional Chinese medicine and its processed products in Gansu Province, meet the characteristics of the province's traditional Chinese medicine industry, the actual clinical needs of traditional Chinese medicine and the needs of quality supervision of traditional Chinese medicine, and provide technical basis for scientific research, production and clinical use of traditional Chinese medicine granules in Gansu Province, as well as technical guarantee for quality supervision of traditional Chinese medicine granules On February 13 this year, foci pharmaceutical announced that it had received the notice on determining the first batch of scientific research units of TCM formula granules in Gansu Province, and determined that the company was one of the first batch of scientific research units of TCM formula granules in Gansu Province At that time, fosci pharmaceutical said that this matter is conducive to improving the company's scientific research level, enriching the company's product structure, building a new profit growth point, and further improving the company's performance Former title: foci pharmaceutical, together with HongRi pharmaceutical, jointly develops the market of Northwest Chinese medicine formula granules reporter: Zhang Min